Search results for: bind therapeutics

By Chris Reidy | GLOBE STAFF JUNE 19, 2014 – Bind Therapeutics Inc., a Cambridge-based nanomedicine company that is developing programmable drugs to certain types of cancer, said Thursday it has entered into a research agreement with Swiss drug giant Roche [...]

CAMBRIDGE, Mass. (EON: Enhanced Online News) BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering [...]